Fargo, North Dakota, April 26, 2021 (GLOBE NEWSWIRE) –
|Genovac Antibody Discovery was launched in the US following a management buyout of an antibody discovery business from Aldevron, a US-based contract manufacturing organization. The unit, which was founded and operated in Freiburg, has its headquarters in Fargo, ND |
Brian Walters, who was previously President of Aldevron’s Antibody Discovery Group, led the management buyout and is now President and CEO of Genovac.
Genovac is a contract research organization that discovers and develops antibodies for therapeutic, diagnostic, and research and development market segments with customers in North America, Europe, Australia and Asia. The company’s core technology, genetic immunization, enables the rapid discovery of antibodies against the most challenging targets in biopharmaceuticals.
The company has been in the biopharmaceutical industry for more than 20 years and has completed over 3,500 projects providing antibodies that have been developed into clinical and commercial drugs. Genovac has also completed more than 25 customer and internal COVID-19 campaigns and developed two antibodies that successfully neutralize the mutations in the UK, Brazil and South Africa.
In addition to genetic immunization, Genovac has acquired the world’s most advanced single cell screening technology, the beacon® Optofluidic system developed by Berkeley Lights. The platform enables Genovac to produce DNA for genetic immunization in a week compared to the months it would take to detect antibodies using the traditional protein-based method. By combining its expertise in genetic immunization with advanced, one-day single-cell screening technology, Genovac can rapidly generate antibodies, a critical element in drug development to treat infectious diseases such as the coronavirus and its mutations.
Genovac was also the first beacon system user in the world to successfully screen wild-type and transgenic rat cells. The company is currently striving to be the first to screen rabbit and alpaca cells. All are rich in sources of antibodies that can be developed into human therapeutics.
Walters was Aldevron’s chief financial officer before heading the Antibody Discovery Group. Prior to that, he held several management positions in business development organizations in the United States.
You can find more information on our Website.
– 30 –